China
Africa
Explore chapters and articles related to this topic
Prednicarbate
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
A 37-year-old woman working as waitress presented with desquamative lesions on the backs of both hands that had been resistant to treatment with various topical (including prednicarbate) and systemic corticosteroids for a year. Skin biopsy showed spongiotic dermatitis. Patch tests were positive to budesonide and hydrocortisone 17-butyrate in the baseline series (not previously used by the patient), and to prednicarbate cream 0.25%. When patch tested with the active and inactive ingredients of prednicarbate cream, positive ring-shaped reactions to prednicarbate 0.1% and 1% alcohol (++) and 1% water (+) were seen at D2, D4, and D7 (3).
Topical Corticosteroids
Published in John Y. M. Koo, Ethan C. Levin, Argentina Leon, Jashin J. Wu, Mark G. Lebwohl, Mild to Moderate Psoriasis, 2014
Laura F. Sandoval, Steven R. Feldman
Improving the safety profile of topical corticosteroids while maintaining potency has proven elusive. Creating nonfluorinated potent corticosteroids is not the solution; it is the strength of the corticosteroid, not the fluorine atom covalently bound in the molecule, that contributes to adverse events. There is no reason whatsoever to expect that potent nonfluorinated corticosteroids will have fewer or less severe side effects than fluorinated corticosteroids of equal potency. Mometasone furoate uses chlorination rather than fluorination to achieve potency. Some studies claim a reduced risk of adverse effects with mometasone furoate [32,49]. These studies, however, were not adequately designed to demonstrate comparable potency while decreasing adverse event rates. For example, one study comparing mometasone to hydrocortisone found greater potency with mometasone but not significantly greater adverse events; this study was powered to find differences in efficacy but was not powered to identify the likely real differences in adverse event profiles [50]. Studies of the nonfluorinated prednicarbate have also claimed a dissociation between benefit and risk. Although both a reduction in adverse effect rate and equal potency have been demonstrated independently [34,35,51,52], studies have not shown the occurrence of both outcomes simultaneously under identical conditions. Therefore, we conclude that the existence of safer topical corticosteroids with equal potency is yet to be demonstrated.
Face and neck rejuvenation using an improved non-ablative fractional high power 1064-nm Q-switched Nd:YAG Laser: clinical results in 16 women
Published in Journal of Cosmetic and Laser Therapy, 2020
Fernando Urdiales-Gálvez, Mario A. Trelles, Sandra Martín-Sánchez, Mónica Maiz-Jiménez
Upon completing the two passes, first with the 0 tip and second with the +2 tip, a prednicarbate cream 0.25% was applied (Peitel, Grupo Ferrer, Barcelona, Spain), mixed in equal parts with aloe vera gel (Lab. Profarplan, Barcelona, Spain). It was recommended that they avoid direct sun exposure of the treated areas and use sunscreen. No other topical treatment was used during the course of the entire study.